CD8A and diabetes mellitus: Further, studies by our team [22] and others [51] show that inhibiting RAGE by prophylactic soluble RAGE (sRAGE) therapy, a decoy receptor that clears circulating AGEs, elevates numbers of RAGE+ CD4 and CD8 T cells, Treg cells, DCs and macrophages in lymphoid tissue and improves Treg function [22] and prevents the transfer of diabetes by diabetogenic T cells in NODscid mice [51].